Your browser doesn't support javascript.
Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein.
Tani, Hideki; Kimura, Miyuki; Tan, Long; Yoshida, Yoshihiro; Ozawa, Tatsuhiko; Kishi, Hiroyuki; Fukushi, Shuetsu; Saijo, Masayuki; Sano, Kaori; Suzuki, Tadaki; Kawasuji, Hitoshi; Ueno, Akitoshi; Miyajima, Yuki; Fukui, Yasutaka; Sakamaki, Ippei; Yamamoto, Yoshihiro; Morinaga, Yoshitomo.
  • Tani H; Department of Microbiology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan. toyamaeiken3@juno.ocn.ne.jp.
  • Kimura M; Department of Virology, Toyama Institute of Health, Toyama, Japan. toyamaeiken3@juno.ocn.ne.jp.
  • Tan L; Department of Microbiology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
  • Yoshida Y; Department of Microbiology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
  • Ozawa T; Department of Microbiology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
  • Kishi H; Department of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
  • Fukushi S; Department of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
  • Saijo M; Department of Virology I, National Institute of Infectious Diseases, Tokyo, Japan.
  • Sano K; Department of Virology I, National Institute of Infectious Diseases, Tokyo, Japan.
  • Suzuki T; Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
  • Kawasuji H; Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
  • Ueno A; Department of Clinical Infectious Diseases, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
  • Miyajima Y; Department of Clinical Infectious Diseases, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
  • Fukui Y; Department of Clinical Infectious Diseases, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
  • Sakamaki I; Department of Clinical Infectious Diseases, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
  • Yamamoto Y; Department of Clinical Infectious Diseases, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
  • Morinaga Y; Department of Clinical Infectious Diseases, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
Virol J ; 18(1): 16, 2021 01 12.
Article in English | MEDLINE | ID: covidwho-1059645
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
Semantic information from SemMedBD (by NLM)
1. Antibodie PART_OF C5203676
Subject
Antibodie
Predicate
PART_OF
Object
C5203676
2. Coronavirus Infections COEXISTS_WITH Genus: Coronavirus
Subject
Coronavirus Infections
Predicate
COEXISTS_WITH
Object
Genus: Coronavirus
3. 2019 novel coronavirus PROCESS_OF Homo sapiens
Subject
2019 novel coronavirus
Predicate
PROCESS_OF
Object
Homo sapiens
4. Assay USES Luciferases
Subject
Assay
Predicate
USES
Object
Luciferases
5. M Protei PART_OF C5203676
Subject
M Protei
Predicate
PART_OF
Object
C5203676
6. Antibodie DISRUPTS C0162524
Subject
Antibodie
Predicate
DISRUPTS
Object
C0162524
7. COVID-19 PROCESS_OF hospitalized patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
hospitalized patients
8. Antibody titer measurement MEASURES Enzyme-Linked Immunosorbent Assay
Subject
Antibody titer measurement
Predicate
MEASURES
Object
Enzyme-Linked Immunosorbent Assay
9. Antibody titer measurement MEASURES Fluorescent Antibody Technique
Subject
Antibody titer measurement
Predicate
MEASURES
Object
Fluorescent Antibody Technique
10. Laboratory LOCATION_OF Assay
Subject
Laboratory
Predicate
LOCATION_OF
Object
Assay
11. Antibodies, Neutralizing PART_OF 2019 novel coronavirus
Subject
Antibodies, Neutralizing
Predicate
PART_OF
Object
2019 novel coronavirus
12. Coronavirus Infections COEXISTS_WITH Genus: Coronavirus
Subject
Coronavirus Infections
Predicate
COEXISTS_WITH
Object
Genus: Coronavirus
13. 2019 novel coronavirus PROCESS_OF Homo sapiens
Subject
2019 novel coronavirus
Predicate
PROCESS_OF
Object
Homo sapiens
14. Assay USES Luciferases
Subject
Assay
Predicate
USES
Object
Luciferases
15. M Protein, multiple myeloma PART_OF 2019 novel coronavirus
Subject
M Protein, multiple myeloma
Predicate
PART_OF
Object
2019 novel coronavirus
16. Antibodies, Neutralizing DISRUPTS Chemiluminescence
Subject
Antibodies, Neutralizing
Predicate
DISRUPTS
Object
Chemiluminescence
17. COVID-19 PROCESS_OF hospitalized patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
hospitalized patients
18. Antibody titer measurement MEASURES Enzyme-Linked Immunosorbent Assay
Subject
Antibody titer measurement
Predicate
MEASURES
Object
Enzyme-Linked Immunosorbent Assay
19. Antibody titer measurement MEASURES Fluorescent Antibody Technique
Subject
Antibody titer measurement
Predicate
MEASURES
Object
Fluorescent Antibody Technique
20. Laboratory LOCATION_OF Assay
Subject
Laboratory
Predicate
LOCATION_OF
Object
Assay
ABSTRACT

BACKGROUND:

SARS-CoV-2 is a novel coronavirus that emerged in 2019 and is now classified in the genus Coronavirus with closely related SARS-CoV. SARS-CoV-2 is highly pathogenic in humans and is classified as a biosafety level (BSL)-3 pathogen, which makes manipulating it relatively difficult due to its infectious nature.

METHODS:

To circumvent the need for BSL-3 laboratories, an alternative assay was developed that avoids live virus and instead uses a recombinant VSV expressing luciferase and possesses the full length or truncated spike proteins of SARS-CoV-2. Furthermore, to measure SARS-CoV-2 neutralizing antibodies under BSL2 conditions, a chemiluminescence reduction neutralization test (CRNT) for SARS-CoV-2 was developed. The neutralization values of the serum samples collected from hospitalized patients with COVID-19 or SARS-CoV-2 PCR-negative donors against the pseudotyped virus infection evaluated by the CRNT were compared with antibody titers determined from an enzyme-linked immunosorbent assay (ELISA) or an immunofluorescence assay (IFA).

RESULTS:

The CRNT, which used whole blood collected from hospitalized patients with COVID-19, was also examined. As a result, the inhibition of pseudotyped virus infection was specifically observed in both serum and whole blood and was also correlated with the results of the IFA.

CONCLUSIONS:

In conclusion, the CRNT for COVID-19 is a convenient assay system that can be performed in a BSL-2 laboratory with high specificity and sensitivity for evaluating the occurrence of neutralizing antibodies against SARS-CoV-2.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Neutralization Tests / Vesicular stomatitis Indiana virus / Antibodies, Neutralizing / Spike Glycoprotein, Coronavirus / COVID-19 Serological Testing / SARS-CoV-2 / COVID-19 Type of study: Evaluation study Limits: Animals / Humans Language: English Journal: Virol J Journal subject: Virology Year: 2021 Document Type: Article Affiliation country: S12985-021-01490-7

Full text: Available Collection: International databases Database: MEDLINE Main subject: Neutralization Tests / Vesicular stomatitis Indiana virus / Antibodies, Neutralizing / Spike Glycoprotein, Coronavirus / COVID-19 Serological Testing / SARS-CoV-2 / COVID-19 Type of study: Evaluation study Limits: Animals / Humans Language: English Journal: Virol J Journal subject: Virology Year: 2021 Document Type: Article Affiliation country: S12985-021-01490-7